ASCP MLS Examination Study Guide

1. Blood group inheritance and expression

Each parent passes one ABO allele. A and B encode distinct transferases that add different sugars to red-cell precursors; O usually contributes no functional transferase. A and B are codominant, so an AB person expresses both antigens. An AO person expresses A but can transmit O. For Rh, the D antigen is often taught with a simple presence-or-absence model, but Rh genetics involves several closely linked genes and variant expression. Do not infer a complete genotype from routine D typing alone. In other systems, a person may inherit an antigen yet express it weakly or lack it because of modifying genes. Dosage means some antibodies react more strongly with cells carrying two copies of an antigen than with cells carrying one. This matters when selecting panel cells for antibody exclusion. The ASCP Board of Certification lists the MLS credential.

Worked example: An AO parent makes A or O gametes; a BO parent makes B or O gametes. Combining them gives AB, AO, BO, and OO, each with a 1-in-4 probability under ordinary Mendelian inheritance. Their phenotypes are AB, A, B, and O, respectively. An O child is therefore possible because both parents can pass O. This predicts possibilities, not the actual genotype of a particular child.

Watch the distinction: Two parents with A and B phenotypes cannot necessarily have only A, B, or AB children. If both carry O, an OO child has group O.

Reference: [1]

2. Why red cells react

Agglutination is visible clumping after antibodies bridge red cells. Pentameric IgM spans the distance between cells efficiently, often producing direct saline reactions at cooler temperatures. Smaller IgG molecules can coat, or sensitize, cells without visible clumping. After unbound IgG is washed away, antihuman globulin can bridge cell-bound IgG and reveal that sensitization. Some antibodies activate complement; the extent depends on antibody class, antigen density, and reaction conditions. Temperature matters because antibody binding may favor cold or body temperature. Enhancement media can reduce repulsive forces or promote antibody uptake, while centrifugation brings cells close enough to react. Excessive centrifugation may mimic agglutination, so reactions must be read with controls and the method's conditions. Reaction phase suggests a mechanism but does not identify antibody specificity by itself.

Worked example: One serum clumps test cells at immediate spin, then becomes nonreactive after warming. This favors a cold-reactive agglutinin pattern, though specificity still needs testing. Another serum has no visible early reaction but reacts after incubation and the antiglobulin step. That supports an IgG-type antibody; compare its reactions with antigen profiles and check clinically significant specificity before selecting red cells.

Watch the distinction: A negative immediate-spin reaction does not rule out an important antibody. IgG may sensitize cells without visible clumping and become detectable only at the antiglobulin phase.

3. Resolving ABO and Rh discrepancies

Forward grouping tests patient red cells with anti-A and anti-B; reverse grouping tests patient plasma against known A and B cells. The two results should agree, but they answer different questions. Weak antigen expression, recent transfusion, stem-cell transplantation, cold antibodies, or reduced plasma antibodies can disrupt agreement. Check the patient identifiers and collection record first, then inspect reaction strength and any mixed-field appearance, where agglutinated and free cells coexist. Review prior types, transfusion history, age, and relevant therapy. Repeat testing or use selected methods to determine which population or antibody explains the discrepancy. Rh testing also requires attention to method-specific weak or variant D findings. Until the discrepancy is resolved, avoid assigning a routine type or relying on an unsupported electronic compatibility decision. Component selection must protect the patient while investigation continues.

Worked example: A recently transfused patient's red cells show mixed-field agglutination with anti-A and no reaction with anti-B. Plasma reacts with B reagent cells only, a reverse pattern supporting group A. The free red cells could reflect transfused group O cells, but identity, prior records, and transfused-unit history must be checked. Record the unresolved mixed population before choosing routine group-specific components.

Watch the distinction: Reverse grouping that looks like group A does not erase mixed-field forward typing. A second red-cell population may remain and can affect interpretation and compatibility decisions.

4. Finding an unexpected antibody

An antibody panel pairs each test cell's antigen profile with its reaction strength and phase. First identify patterns that fit the reactive cells, then test whether nonreactive cells genuinely exclude competing antibodies. A cell lacking the relevant antigen cannot exclude that antibody; for dosage-sensitive systems, a heterozygous antigen-positive cell may react too weakly to exclude it reliably. Check the autocontrol to assess whether patient cells react with patient plasma, but remember a negative autocontrol does not prove a single alloantibody. Recent transfusion can also complicate phenotyping. Kidd antibodies may show dosage and variable strength, so use selected cells that separate Jka from other candidate antigens. Confirm the proposed specificity with adequate positive and negative cells, then consider the patient's antigen status and transfusion history. Multiple antibodies can produce a composite pattern that initially resembles one specificity.

Worked example: At the antiglobulin phase, Jk(a+b−) panel cells react strongly, Jk(a+b+) cells react weakly, and Jk(a−b+) cells do not react. This supports anti-Jka with dosage. It is not yet a complete identification: choose additional cells that isolate Jka from any other antigen shared by the reactive cells. Use suitably antigen-positive, preferably homozygous nonreactive cells when excluding dosage-sensitive competing antibodies.

Watch the distinction: A single nonreactive heterozygous cell does not safely exclude every dosage-sensitive antibody. Its antigen expression may be too low to produce a detectable reaction.

5. Antiglobulin tests and their controls

The direct antiglobulin test, or DAT, asks whether IgG or complement is already attached to a patient's circulating red cells. The indirect antiglobulin test, or IAT, asks whether plasma antibodies can bind reagent or donor red cells during laboratory incubation. Polyspecific reagent detects IgG and complement; monospecific reagents distinguish the coating type. A positive DAT establishes coating, not its cause or clinical significance. An eluate can strip bound IgG from cells for specificity testing, while adsorption can remove a broadly reactive antibody from plasma to uncover others. Enhancement methods may improve detection but can alter reaction patterns. Antiglobulin testing requires adequate washing so free globulin cannot neutralize reagent. If a negative test's IgG-coated check cells fail to agglutinate, the negative result is invalid because reagent activity or washing cannot be confirmed.

Worked example: A patient has an IgG-positive DAT but a negative plasma antibody screen. IgG may be bound to circulating cells while little detectable antibody remains free in plasma. An eluate can test the cell-bound antibody's specificity. Separately, a negative IAT receives check cells that fail to react. That negative IAT must be repeated after troubleshooting; it cannot be reported as valid.

Watch the distinction: A positive DAT does not automatically establish immune hemolysis. Correlate it with hemolysis markers, timing, transfusion or drug history, and the pattern of cell-bound immunoglobulin.

6. Interference in compatibility testing

Broad reactivity may arise from a warm autoantibody, cold-reactive antibody, rouleaux, mixed-cell populations, or a drug that interferes with the assay. Use reaction phase, autocontrol, DAT, cell appearance, clinical history, and prior antibodies to sort these possibilities. Rouleaux forms coin-stack aggregates in protein-rich plasma and may disperse with saline replacement; true agglutination persists. A recently transfused patient may have more than one red-cell population. Anti-CD38 therapy can cause panreactivity because reagent cells express low levels of CD38. Dithiothreitol, or DTT, treatment reduces that interference but also destroys Kell antigens. Therefore a nonreactive treated-cell screen cannot exclude anti-K. Resolve known alloantibodies and use a validated approach or specialist referral when interference hides clinically significant reactivity.

Worked example: After anti-CD38 therapy, every untreated screening cell reacts, while DTT-treated cells are nonreactive. The change supports drug interference rather than a demonstrated panreactive alloantibody. Because DTT destroys K antigen, anti-K could be masked. If the patient's K-positive status is not known, select K-negative red cells while applying the laboratory's remaining compatibility requirements and reviewing antibody history.

Watch the distinction: A clear DTT-treated screen does not mean all clinically significant antibodies were excluded. Anti-K can be missed because the treated reagent cells no longer express K.

7. Selecting safe blood components

Component selection starts with the patient's identity, ABO/Rh findings, current testing, and historical antibodies. An evanescent alloantibody may fall below detection yet reappear after antigen exposure, so history still governs antigen-negative red-cell selection. A serologic crossmatch tests patient plasma against donor cells when indicated; eligibility for other compatibility routes depends on the complete record and validated process. Match the component to its function: red cells increase oxygen-carrying capacity, platelets support primary hemostasis, plasma supplies multiple coagulation factors, and cryoprecipitate concentrates selected proteins. Irradiation, leukocyte reduction, washing, or other modifications answer distinct clinical questions and are not interchangeable. Donor testing, preparation, approved storage, and transport preserve component safety and function. If urgency outruns completion of testing, use the emergency-release pathway, communicate what remains unresolved, and continue the investigation.

Worked example: A patient needs red cells and has documented anti-E, although today's antibody screen is negative. Select E-negative units and perform the compatibility testing required for that antibody history. The negative screen may reflect antibody decline, not loss of risk. If blood is needed before testing is complete, communicate the unresolved compatibility status, release through the emergency process, and continue testing.

Watch the distinction: A newly negative antibody screen does not cancel a documented clinically significant antibody. Re-exposure to the corresponding antigen may produce an anamnestic response and delayed hemolysis.

8. Investigating a transfusion reaction

When symptoms arise during transfusion, the clinical team stops the transfusion, maintains access as directed, assesses the patient, and promptly alerts the blood bank. The laboratory first checks patient and unit identity, labels, records, and the returned component. Compare pretransfusion and posttransfusion plasma for new hemolysis, repeat ABO/Rh testing when indicated, and compare DAT results. A new positive DAT with hemolysis raises concern for immune destruction, but mechanical damage, specimen hemolysis, and other causes must be assessed. Fever can also signal bacterial contamination or a nonhemolytic reaction; targeted cultures and other studies follow the presentation. Examine urine, hemolysis markers, and component findings as appropriate. Document findings and urgent communication while the clinical team manages the patient. The laboratory's role is to establish the testing pattern and escalate risk, not independently assign a definitive clinical diagnosis.

Worked example: Fever and dark urine begin during a red-cell transfusion. The posttransfusion plasma is newly hemolyzed, and the DAT has changed from negative to positive. These findings strongly warrant immediate escalation for suspected immune hemolysis. Check the bedside and laboratory identification chain, repeat relevant typing and compatibility studies, and investigate other indicated causes while preserving the unit and specimens for testing.

Watch the distinction: Fever alone does not classify a transfusion reaction. New hemolysis and DAT conversion change the concern, while clerical, immune, infectious, and nonimmune possibilities still require investigation.

9. Maternal, neonatal, and platelet antibodies

Maternal IgG can cross the placenta and bind fetal red-cell antigens, causing hemolysis or suppression of red-cell production. Investigate the maternal antibody, its clinical significance, and whether the fetus or newborn carries the corresponding antigen. Infant DAT, hemoglobin, bilirubin, and clinical timing add evidence, but DAT strength alone does not measure disease severity. Rh immune globulin is passive anti-D intended to prevent an eligible D-negative person's immune response to D-positive fetal cells; it does not treat established anti-D alloimmunization. Fetomaternal hemorrhage measurement can guide additional dosing under a stated product and policy rule. Platelet problems follow different antigens: maternal platelet-specific antibodies can affect a newborn, while HLA antibodies can contribute to poor increments after platelet transfusion. Confirm refractoriness with appropriately timed increments and investigate nonimmune consumption before specialized HLA or platelet-antigen testing.

Worked example: Suppose a case policy states that one Rh immune globulin dose covers 30 mL of fetal whole blood and requires rounding up. A validated fetomaternal hemorrhage estimate is 40 mL. Then 40 ÷ 30 = 1.33, so two doses meet that stated rule. In a separate patient with repeatedly poor platelet increments and HLA antibodies, request a specialized refractoriness assessment rather than applying red-cell antibody logic.

Watch the distinction: A positive infant DAT does not quantify hemolytic disease, and platelet refractoriness is not explained solely by HLA antibodies. Timing, counts, and other causes matter.

10. How the nephron shapes urine

Glomerular filtration moves water and small solutes into the nephron while normally retaining most cells and large proteins. Tubules reclaim needed water, glucose, and electrolytes, and secrete selected ions and compounds. Thus urine findings can locate a process: substantial protein with dysmorphic erythrocytes and red-cell casts favors glomerular injury; isolated tubular wasting points toward impaired reabsorption. Red-cell casts form within renal tubules, so they locate bleeding above the lower urinary tract. Free intact erythrocytes without casts are less specific and may reflect stones, infection, contamination, or collection trauma. Concentration depends on tubular function, hormones, and hydration, so a single urine result requires context. For wider connections among disciplines, see the medical laboratory scientist certification guide. The MLS reports and interprets the laboratory pattern without assigning a diagnosis from urine alone.

Worked example: A fresh urine sample has protein, dysmorphic erythrocytes, and red-cell casts. The casts formed in renal tubules, while distorted red cells and protein support a glomerular source. In another sample obtained after a traumatic collection, many intact free erythrocytes appear without casts. That result documents blood in the specimen but does not establish glomerular bleeding; collection trauma remains plausible.

Watch the distinction: Many urinary erythrocytes do not automatically mean glomerulonephritis. Cell shape, protein, casts, collection quality, and other findings determine how strongly a renal source is supported.

11. Collection and storage effects

Urine continues to change after collection. Warm, unpreserved storage permits bacterial multiplication, which may consume glucose and produce alkaline metabolites; cells also metabolize glucose. Leukocytes and erythrocytes can lyse, especially in dilute or alkaline urine, reducing microscopic counts despite earlier inflammation or bleeding. Casts deteriorate with delay. Light can degrade bilirubin, while refrigeration slows biological change but may precipitate amorphous crystals and affect apparent clarity. Preservatives may protect particular analytes yet interfere with others, so the container must match the requested tests. Collection method affects contamination: a poorly collected voided sample may contain genital cells or mixed flora, whereas an invasive sample has different handling risks. Record collection time, storage, and container before treating a surprising result as patient physiology.

Worked example: An unpreserved voided sample remains warm for several hours. It later has higher pH, less glucose, and fewer intact cells than expected. Bacterial growth can raise pH, while bacteria and cells consume glucose; cells may also lyse during storage. These changes weaken conclusions about the patient's original urine. Seek a fresh, properly handled specimen when the discordance affects interpretation.

Watch the distinction: A delayed urine sample's low glucose and sparse cells are not necessarily original patient findings. Storage can change chemistry and destroy formed elements before examination.

12. Concentration and physical appearance

Color and clarity describe visible properties, not concentration by themselves. Pigments, medications, blood, crystals, cells, and bacteria can change appearance. Specific gravity compares urine density with water and depends partly on solute mass. A refractometer infers it from refractive index, so large molecules or radiographic contrast can raise the reading disproportionately. A reagent-strip specific-gravity pad responds mainly to ionic concentration and may disagree when unusual nonionic solutes are present. Osmolality measures the number of dissolved particles per kilogram of solvent, largely regardless of each particle's size. Compare methods according to the question: osmolality better reflects particle concentration, while specific gravity is a useful but method-dependent estimate. Check calibration, temperature compensation where relevant, and specimen context before calling a disagreement an instrument failure.

Worked example: After radiographic contrast exposure, a patient's urine gives a high refractometer specific gravity but only modest osmolality. Contrast molecules contribute substantial mass and alter refractive index, while osmolality counts particles rather than their mass. The mismatch is therefore plausible. A strip result may differ too because its pad primarily senses ionic solutes. Report each measurement by its method and interpret the contrast history.

Watch the distinction: High refractometer specific gravity does not always mean proportionally high osmolality. Large or unusual solutes can affect optical and density estimates more than particle count.

13. Reading the reagent strip

Reagent-strip pads detect chemical reactions, so a positive pad is not always the named substance seen under a microscope. The blood pad uses heme's pseudoperoxidase activity and can respond to intact red cells, free hemoglobin, or myoglobin. The protein pad is most sensitive to albumin and can miss other proteins. Glucose uses an enzymatic oxidation reaction; the common ketone pad mainly detects acetoacetate, not every ketone body. Nitrite requires nitrate-reducing organisms and sufficient bladder dwell time. Leukocyte esterase reflects granulocyte enzyme activity, including from lysed cells. Bilirubin and urobilinogen pads depend on different reactions and are vulnerable to light, timing, and chemical interference. pH reflects hydrogen-ion activity at collection, which can change during storage. Read each pad at its specified time and resolve discordant chemistry, microscopy, and clinical findings.

Worked example: A fresh urine sample has a strongly positive blood pad, yet microscopy shows no erythrocytes. The pad detects heme activity, so free hemoglobin or myoglobin is plausible; microscopic hematuria is not demonstrated. Review plasma appearance, hemolysis evidence, muscle-injury findings, and collection conditions. If red cells had lysed in dilute urine, that could also produce the mismatch, so specific context guides follow-up.

Watch the distinction: A positive blood pad is not proof of intact urinary red cells. Heme-containing pigments and lysed cells can trigger the reaction without visible erythrocytes.

14. Recognizing sediment elements

Sediment identification begins with shape, internal structure, and the background urine. Erythrocytes are small discs without nuclei; leukocytes are larger and granular, sometimes with visible nuclei. Epithelial-cell type helps assess whether cells arose from skin, lower tract, or renal tubules, although morphology needs care. Casts are cylindrical molds of protein formed in distal nephron segments; embedded cells or granules determine their name. Crystals have geometric shapes influenced by pH, concentration, and cooling, but common crystals do not automatically imply disease. Bacteria and yeast must be distinguished from debris and contamination. Air bubbles, fibers, and starch can mimic formed elements. Focus through the structure: a cell truly enclosed within a cast differs from a cell merely lying over it. Relate morphology to chemistry and specimen age before reporting its significance.

Worked example: A cylindrical structure has parallel sides and erythrocytes enclosed in its protein matrix. Identify it as a red-cell cast. Free erythrocytes may accompany it but do not explain the cylindrical mold; a crystal aggregate lacks that cast matrix. Because casts form within renal tubules, the finding supports a renal source of bleeding. Confirm the morphology across the focal plane before reporting.

Watch the distinction: Red cells lying beside or over a hyaline cast do not create a red-cell cast. The erythrocytes must be embedded within the cylindrical matrix.

15. Integrating urine findings

Interpret urine chemistry and microscopy as a single pattern. Leukocyte esterase supports pyuria, while nitrite supports bacteria capable of reducing nitrate under suitable conditions; either pad may be negative despite infection. Microscopic leukocytes and bacteria add evidence, but squamous epithelial cells and mixed flora can suggest collection contamination. A blood-positive pad with few red cells prompts consideration of pigment or cell lysis. Protein with dysmorphic red cells or casts shifts attention toward renal disease rather than simple lower-tract bleeding. Timing matters: delayed examination can destroy cells and allow bacteria to multiply. Symptoms, collection method, and culture findings determine how strongly a pattern supports infection, colonization, or contamination. Report the observed laboratory findings clearly and flag discordance for appropriate follow-up. MLS(ASCP) practice questions can reinforce these paired chemistry-and-sediment decisions.

Worked example: A symptomatic patient's fresh urine has negative nitrite, positive leukocyte esterase, and many leukocytes and bacteria on microscopy. Nitrite negativity does not rule out infection: the organism may not reduce nitrate, or urine may not have remained in the bladder long enough. The other findings support inflammation with bacteriuria. Assess collection quality and culture results before deciding whether the growth is clinically significant.

Watch the distinction: A negative nitrite pad is not a negative infection test. Organism metabolism, dietary nitrate, and bladder dwell time can all prevent a positive reaction.

16. Counting body-fluid cells

A chamber count converts observed cells to concentration using dilution and the volume actually counted. Divide the counted cells by chamber volume, then multiply by the dilution factor to recover the original specimen concentration. Confirm the chamber's calibrated depth and square area before using a volume; a wrong volume creates a systematic error. Mix the specimen gently so cells are distributed evenly and compare duplicate counts when required. Clots trap cells, making the remaining fluid unrepresentative. Debris or very low counts may trigger automated-analyzer flags and require a manual method or alternate preparation. Cerebrospinal fluid cells deteriorate quickly, so prompt counting and differential preparation protect the result. A bloody collection can complicate interpretation across sequential tubes; compare appearance and counts cautiously rather than applying an unsupported universal correction.

Worked example: After a 1:10 dilution, 100 cells are counted in four squares, each holding 0.1 µL. Total counted volume is 4 × 0.1 = 0.4 µL. The diluted fluid contains 100 ÷ 0.4 = 250 cells/µL; the original contains 250 × 10 = 2,500 cells/µL. If the original specimen clotted, trapped cells make this calculated concentration unreliable.

Watch the distinction: Multiplying 100 cells by the dilution factor alone gives no concentration. Divide by the counted chamber volume first, and reject a count from unrepresentative clotted fluid.

17. Serous and synovial fluid clues

Paired serum and serous-fluid measurements can distinguish processes better than a fluid value alone. For ascites, the serum-minus-ascites albumin gradient reflects an underlying pressure relationship when both specimens are appropriately paired; apply the decision point supplied with the case rather than assuming one for every method or setting. Total protein and cell findings may add context but answer different questions. Synovial-fluid crystal identification requires both morphology and compensated polarized-light behavior. Monosodium urate crystals are typically slender needles with negative birefringence; calcium pyrophosphate crystals are often rhomboid or short rods with positive birefringence. Orientation can alter apparent brightness, so rotate the specimen and check the slow-axis convention. A crystal finding does not exclude concurrent infection. Assess sample volume, clotting, and handling before treating a negative crystal search as definitive.

Worked example: Paired serum albumin is 4.0 g/dL and ascitic albumin is 2.5 g/dL. The gradient is 4.0 − 2.5 = 1.5 g/dL, above this case's supplied 1.1 g/dL decision point. It supports the higher-gradient category under that rule. In a separate synovial sample, needle-shaped, negatively birefringent crystals favor urate; rhomboid, positively birefringent crystals favor calcium pyrophosphate.

Watch the distinction: Do not classify synovial crystals by shape alone. Confirm birefringence and orientation, and remember that finding crystals does not rule out joint infection.

18. Special body-fluid specimens

Special body-fluid testing is highly sensitive to what was collected and when. The first semen fraction is usually sperm-rich, so loss of it can falsely lower total sperm number even if a measured concentration looks plausible. Record collection completeness, abstinence and transit details supplied by the laboratory, and analyze within the method's validated timing. For fecal tests, preservatives and containers differ by target: a preservative suitable for parasite morphology may be unsuitable for another assay, and intermittent shedding limits a single negative examination. Amniotic-fluid interpretation depends on the requested question, gestational context, maternal blood contamination, and light protection for susceptible analytes. Across all three, inspect labeling, specimen condition, controls, and method limits. A compromised sample should be qualified or recollected rather than converted into an apparently precise biological conclusion.

Worked example: A patient reports losing the first fraction of a semen collection, while the laboratory measures a low total sperm count in the received portion. Because the missing fraction is sperm-rich, the measured total may underestimate the complete ejaculate. Document the loss and arrange a valid repeat under the laboratory's collection instructions. Do not interpret the incomplete specimen as proof of impaired sperm production.

Watch the distinction: A technically precise count from an incomplete semen collection is still biologically misleading. Missing the first fraction can lower the observed total sperm number.

19. Specimen suitability in chemistry

Serum is the fluid remaining after clotting; plasma retains anticoagulant, and whole blood includes cells. Select the matrix validated for the assay because additives can alter results: EDTA binds calcium and may contribute potassium, while heparin has different assay effects. Collection timing matters for analytes that change after meals, dosing, or over a daily cycle. Delay in separating cells permits glycolysis and may change potassium or other measurements. Hemolysis releases intracellular contents and can also interfere optically; lipemia scatters light, while icterus affects some photometric reactions. Infusion-fluid contamination can dilute or add analytes, creating a pattern across results. Compare the specimen's appearance, interference index, collection site, and related analytes before treating an unexpected result as physiology. A new specimen is useful when the original cannot support a reliable value.

Worked example: A visibly hemolyzed serum specimen gives potassium of 6.2 mmol/L, compared with a recent 4.3 mmol/L result, while other findings are stable. Red-cell rupture can release potassium into serum, so the new value may be falsely high. Assess the method's interference information and promptly communicate any unresolved risk. Obtain a suitable redraw when indicated; do not diagnose hyperkalemia from the compromised sample alone.

Watch the distinction: A high potassium result from hemolyzed serum is not automatically the patient's circulating concentration. Red-cell release can raise the measured value after collection.

20. Signals, calibration, and interference

An instrument converts a chemical or binding event into a signal, then uses calibration to estimate concentration. Spectrophotometry measures light absorption; electrodes measure electrical potential or current; immunoassays convert antigen-antibody binding into optical or luminescent signal. Chromatography separates compounds before measurement, and mass spectrometry distinguishes ions by mass-to-charge behavior. Each method has a validated analytical measurement range; outside it, direct signal cannot be trusted without an approved dilution or alternate method. Carryover can make a specimen after a very high sample appear falsely elevated. Matrix effects alter signal recovery, and immunoassay antibodies or excess analyte can disrupt expected binding. In some sandwich assays, a high-dose hook effect yields a deceptively low neat result because both binding partners are saturated. Check dilution recovery, controls, calibration, and alternate-method agreement before reporting a corrected concentration.

Worked example: A sandwich immunoassay reports 40 units/L on a neat specimen. After validated 1:10 and 1:20 dilutions, measured values are 45 and 23 units/L, giving back-calculated values of 450 and 460 units/L. Their agreement, far above the neat result, suggests a high-dose hook effect. Confirm that diluted readings and corrected concentrations lie within validated ranges before reporting; neither the original 40 nor an unvalidated extrapolation is acceptable.

Watch the distinction: A low neat immunoassay result can be falsely low when analyte is extremely abundant. Serial dilution may reveal a hook effect, but corrected values require validated recovery.

21. Dilutions and reportable results

A dilution lowers an analyte concentration so the instrument can measure it within its analytical measurement range. For a 1:4 dilution, one volume of specimen is brought to four total volumes; multiply the measured concentration by four to estimate the original concentration. Check that the diluent, procedure, and multiplication factor have been verified for that assay. The detection limit is the lowest signal distinguishable from background; it does not mean results there are precise enough to quantify. The analytical measurement range covers concentrations measured directly. The reportable range may extend further through validated dilutions or concentrations. Convert units only after identifying the analyte and its required conversion factor: mass and molar units depend on molecular mass. A calculated value outside the established reportable range cannot be released merely because the diluted aliquot produced an in-range signal.

Worked example: A specimen is mixed as one part specimen plus three parts diluent, giving a 1:4 dilution. The diluted aliquot measures 450 units/L, within the direct measurement range. The original estimate is 450 × 4 = 1,800 units/L. Release that value only if this dilution is validated, quality checks pass, and 1,800 units/L falls within the assay's established reportable range; otherwise, investigate further.

Watch the distinction: A common error is to multiply by three because three parts diluent were added. The dilution factor is four: it describes the final volume relative to the specimen volume.

22. Glucose and glycated markers

Blood glucose reflects the balance among intestinal absorption, hepatic glucose output, tissue uptake, and hormonal regulation at collection. Collection timing therefore matters: a fasting specimen, a specimen after a meal, and a timed challenge sample answer different questions. Blood cells continue consuming glucose after collection, so delayed separation can lower the measured value unless the collection system adequately limits glycolysis. Glycated hemoglobin reflects glycation accumulated during red-cell circulation rather than glucose at one moment. Shortened red-cell survival can lower it relative to the true glucose history; altered hemoglobin or an assay-specific interference can also distort a result. Glycated serum proteins reflect a shorter period and are influenced by protein turnover. When markers disagree, check collection conditions, red-cell history, and the assay method before treating one result as decisive.

Worked example: An unseparated specimen left at room temperature measures glucose at 65 mg/dL. A promptly separated redraw measures 90 mg/dL. The difference is 90 − 65 = 25 mg/dL; continued cellular glycolysis plausibly lowered the first result. Because the samples were collected at different times, that mechanism is an explanation to investigate, not proof that both had identical glucose at collection. Neither result alone establishes a diagnosis.

Watch the distinction: Glycated hemoglobin is sometimes treated as a direct check on a single glucose result. It reflects exposure over red-cell lifespan and can mislead when that lifespan changes.

23. Proteins and lipoproteins

Albumin contributes substantially to plasma oncotic pressure and carries many drugs and hormones. A low concentration may reflect reduced synthesis, loss, inflammation, or dilution, so it needs context. Serum protein electrophoresis separates proteins by migration: a broad increase across the gamma region favors a diverse immunoglobulin response, whereas a narrow band suggests a restricted protein population. Immunofixation then identifies the heavy-chain and light-chain types associated with that band; quantitative immunoglobulins measure amount but do not establish clonality alone. For lipids, distinguish measured cholesterol fractions from calculated values. A calculation is reliable only under the formula's stated specimen and concentration conditions; high triglycerides or unusual lipoproteins can invalidate assumptions. Read electrophoretic pattern, immunofixation, and lipid calculations as laboratory findings that guide further evaluation rather than as stand-alone clinical diagnoses.

Worked example: Electrophoresis shows a persistent narrow gamma-region band. Immunofixation identifies IgG paired with kappa light chain in that position. The matching restricted band supports a monoclonal IgG-kappa protein finding, unlike a broad inflammatory increase. Its concentration, persistence, other laboratory results, and clinical findings determine significance; the band alone does not distinguish every possible underlying condition.

Watch the distinction: A raised total immunoglobulin concentration does not automatically mean a monoclonal protein. Multiple antibody populations can produce a broad increase; a restricted band requires pattern review and characterization.

24. Renal markers and clearance

Creatinine is produced from muscle creatine and cleared mainly by glomerular filtration, so serum concentration depends on both production and kidney handling. Changes in muscle mass, diet, or assay interference can shift serum creatinine without the same change in filtration. Urea also responds to protein metabolism, hydration, and tubular reabsorption. A timed creatinine clearance uses urine creatinine concentration multiplied by urine flow rate, then divided by a contemporaneous serum creatinine concentration. Convert total urine volume into mL/min before calculating. An incomplete collection lowers measured total urinary excretion and can make clearance falsely low; an incorrect collection interval changes the flow calculation. The result approximates filtration but may exceed true filtration because some creatinine is secreted by tubules. Compare it with specimen history and other renal findings before interpretation.

Worked example: Urine creatinine is 120 mg/dL, the recorded 24-hour urine volume is 1,000 mL, and serum creatinine is 1 mg/dL. Urine flow is 1,000 ÷ 1,440 = 0.694 mL/min. Clearance is (120 ÷ 1) × 0.694 = 83.3 mL/min. The mg/dL units cancel. This estimate assumes the full 24-hour urine was collected and serum creatinine was reasonably stable.

Watch the distinction: Dividing by 24 instead of 1,440 gives a volume per hour, not per minute. Also, a mathematically correct clearance remains unreliable when the timed collection is incomplete.

25. Electrolytes and acid-base patterns

Sodium is the main measured extracellular cation; chloride and bicarbonate are major measured anions. The anion gap estimates the difference between measured cations and anions and can flag an accumulation of unmeasured anions. Using a formula without potassium, calculate sodium minus chloride plus bicarbonate in parentheses. Albumin is an important unmeasured anion, so low albumin can conceal an increased gap. Interpret the gap with pH, carbon dioxide tension, bicarbonate, and the case's reference interval: a low bicarbonate supports a metabolic process, while respiratory compensation requires blood-gas assessment. Measured osmolality counts dissolved particles, whereas electrolyte concentrations also depend on water balance and measurement method. Check specimens for artifacts: saline contamination can alter several electrolytes, excess liquid anticoagulant can dilute blood gases, and air exposure can change oxygen and carbon dioxide measurements.

Worked example: A case provides sodium 140, chloride 104, and bicarbonate 12 mmol/L, with an anion-gap reference interval of 8 to 16 mmol/L using a formula without potassium. The gap is 140 − (104 + 12) = 24 mmol/L, above that interval. The low bicarbonate and raised gap support an unmeasured-anion metabolic process, but pH, carbon dioxide, albumin, and specimen quality are needed to characterize the full acid-base pattern.

Watch the distinction: A raised gap is not a diagnosis or a complete blood-gas interpretation. Low albumin and collection artifacts can change the calculation's meaning, so check both before drawing conclusions.

26. Tissue markers over time

A tissue marker becomes useful when its source, release mechanism, clearance, and time course fit the question. Aminotransferases reflect cellular injury but differ in tissue distribution; alkaline phosphatase and gamma-glutamyl transferase can help assess a cholestatic pattern. Direct and indirect bilirubin fractions help distinguish impaired conjugation or increased bilirubin production from impaired excretion, though patterns overlap. Creatine kinase may rise with muscle injury, and cardiac biomarkers require assay-specific interpretation. Serial samples can separate a changing release pattern from a stable elevation, provided collection times and analytical methods are comparable. A rising value does not identify the cause by itself. Check hemolysis, interfering antibodies, method changes, and accompanying tests when a result conflicts with the clinical picture. The laboratory reports and communicates the supported pattern while clinical assessment determines diagnosis.

Worked example: A cardiac marker measures 8, then 32, then 70 ng/L in samples collected at stated intervals on the same assay. The changes are +24 and +38 ng/L; the overall rise is 62 ng/L. This dynamic pattern is more consistent with a recent or continuing release than with a stable elevation. Interpretation still needs the assay's decision limits, sampling times, symptoms, and other findings.

Watch the distinction: One elevated marker value cannot date an injury or identify its cause. Serial change adds information, but different assays or poorly documented collection times can make a trend misleading.

27. Hormones, drugs, and specialized chemistry

Endocrine results should fit a feedback loop and a collection schedule. For example, a low target-gland hormone may stimulate its controlling pituitary hormone if the axis is intact, whereas binding-protein changes can alter total hormone without similarly changing free hormone. Circadian rhythms, medicines, stimulation tests, and suppression tests add timing requirements. Therapeutic drug monitoring has the same constraint: a trough is collected just before the next scheduled dose after considering the dosing plan, while a post-dose concentration answers a different question. Screening toxicology immunoassays may cross-react with related compounds; a specific confirmatory method addresses a different analytical claim. Nutritional markers and trace elements can be affected by inflammation, contamination, or recent intake. When results conflict, examine timing, specimen type, method, and interference before assigning physiological meaning.

Worked example: A drug level is labeled “trough,” but the chart shows collection two hours after administration and several hours before the next scheduled dose. The number may be analytically valid, yet it cannot be compared with a trough decision range. Record the actual collection and dose times, communicate the mismatch, and obtain a correctly timed specimen if a trough is needed.

Watch the distinction: The word “trough” on a request does not establish specimen timing. Interpreting a post-dose result as a trough can falsely suggest excessive exposure or inappropriate dosing.

28. Marrow maturation and specimen quality

Marrow precursors mature into circulating red cells, leukocytes, and platelets. A peripheral smear may show increased immature granulocytes during strong marrow stimulation, but blasts, marked dysplasia, or several reduced cell lines need broader review. Specimen integrity comes first: EDTA prevents clotting for a CBC, and adequate filling and immediate gentle mixing distribute it through the sample. A clot can trap platelets and leukocytes, producing falsely low counts. Excess EDTA from underfilling may alter cell morphology, while aging can distort leukocytes and enlarge platelets or red cells enough to affect classification. Make a smear promptly when morphology matters, inspect for clots and analyzer flags, then decide whether the specimen supports reporting. The medical laboratory scientist can identify an unreliable sample and escalate concerning findings without assigning a marrow diagnosis from one smear.

Worked example: A CBC reports platelets of 38 × 10³/µL, but the EDTA tube contains a visible small clot. Platelets can be incorporated into that clot, so the numerical result may be falsely low. Hold interpretation, document the defect, and obtain a properly collected, mixed specimen according to laboratory procedure. Evaluate the repeat count and smear before treating thrombocytopenia as a patient finding.

Watch the distinction: A tiny clot is not harmless because the analyzer samples only the remaining liquid. A platelet count from that liquid may look precise while missing trapped cells.

29. Automated count disagreements

Impedance counters register changes in electrical resistance as cells pass an aperture; optical systems use scattered light and sometimes fluorescence to estimate size and internal features. Hemoglobin is commonly measured after red cells are lysed, while hematocrit and indices may be calculated from counts and volumes. These linked measurements provide consistency checks. Red-cell agglutinates can be counted as fewer, larger particles, lowering the red-cell count and raising apparent MCV and calculated MCHC. Platelet clumps can lower platelet counts or trigger size-based flags. Nucleated red cells may enter an uncorrected white-cell count, and coincidence occurs when multiple cells pass a detector together. Review flags and a smear, then use an appropriate corrective method before release. The related medical laboratory technician guide can reinforce basic count and index calculations.

Worked example: At room temperature, a specimen shows red cells 2.1 × 10⁶/µL, MCV 125 fL, and MCHC 42 g/dL, with a smear showing clumps. After validated warming and repeat analysis, the red-cell count is 3.7 × 10⁶/µL and the indices become plausible. Cold-reactive red-cell agglutination explains why the initial instrument counted aggregates as large particles; review the corrected results and smear together.

Watch the distinction: An implausibly high MCHC does not necessarily mean unusually hemoglobin-rich cells. It often signals an analytical inconsistency, especially when red-cell clumping or specimen interference is present.

30. Red-cell indices and absolute counts

Red-cell indices connect independently measured hemoglobin, hematocrit, and red-cell count. With hematocrit in percent and red cells in millions/µL, MCV in fL equals hematocrit × 10 ÷ red-cell count. MCH in pg equals hemoglobin in g/dL × 10 ÷ red-cell count. MCHC in g/dL equals hemoglobin × 100 ÷ hematocrit. MCV describes average cell volume; MCHC describes hemoglobin concentration within the red-cell mass. Calculate absolute leukocyte counts by multiplying the total white-cell count by the differential fraction, then consider whether nucleated red cells require a corrected white-cell count. A reticulocyte percentage also needs context: anemia lowers the red-cell denominator, so an apparently high percentage may represent a modest production response. Use the stated correction formula and check the smear against the calculated pattern.

Worked example: Hematocrit is 30%, red cells are 5.0 × 10⁶/µL, and hemoglobin is 9 g/dL. MCV = 30 × 10 ÷ 5.0 = 60 fL; MCH = 9 × 10 ÷ 5.0 = 18 pg; MCHC = 9 × 100 ÷ 30 = 30 g/dL. The low volume and concentration support a microcytic, hypochromic pattern, which the smear should corroborate.

Watch the distinction: A low MCV alone does not identify the cause of anemia. Indices describe cells; iron studies, reticulocytes, morphology, and patient context explain how the pattern arose.

31. Working through anemia patterns

Begin an anemia workup by asking whether marrow output is adequate for the degree of anemia. A low or inappropriately normal reticulocyte response points toward limited production; an increased response directs attention to blood loss or shortened red-cell survival. Then use MCV and smear morphology to refine the possibilities. Microcytosis with low ferritin supports depleted iron stores, while microcytosis with preserved iron stores may require consideration of other causes. Macrocytosis with oval cells and hypersegmented neutrophils supports a megaloblastic process; round macrocytes can arise through other mechanisms. Polychromasia reflects reticulocytes and may accompany hemolysis or recovery. Increased indirect bilirubin and lactate dehydrogenase with low haptoglobin can support hemolysis, but each marker has limitations. Integrate findings before choosing targeted studies or escalating unexpected cells.

Worked example: Patient A has hemoglobin 9 g/dL, MCV 68 fL, low ferritin by the case's reference interval, and a reticulocyte response below that expected for anemia. Those findings support iron-restricted production. Patient B has anemia, marked polychromasia, increased reticulocytes, and increased indirect bilirubin. That pattern directs investigation toward blood loss or hemolysis rather than the same production mechanism.

Watch the distinction: A high raw reticulocyte percentage can exaggerate marrow adequacy in anemia because the denominator is smaller. Assess the response relative to anemia severity before calling production sufficient.

32. Hemoglobin disorder testing

Hemoglobin screening and separation tests answer different questions. A sickling-solubility method detects whether sufficient hemoglobin S is present to make a reduced sample turbid; it does not distinguish trait from disease or identify every coexisting variant. Electrophoresis, high-performance liquid chromatography, and capillary methods separate fractions by charge or other properties, but some variants overlap in a given system. A second method or molecular study may be needed for definitive characterization. Age changes expected fractions: fetal hemoglobin predominates early in life. Recent transfusion introduces donor red cells and hemoglobin, so the measured pattern may not represent the patient's own production. Review transfusion history, age, and method-specific peaks before reporting an interpretation. A negative screening result can also be misleading when the relevant fraction is too small for detection.

Worked example: A sickling-solubility screen is positive in a patient transfused three weeks ago. It indicates hemoglobin S was detected in the tested blood, but donor cells can alter the fraction pattern and the screen cannot distinguish possible genotypes. Review pretransfusion results if available, perform an appropriate separation method, and interpret its fractions with the transfusion history before characterizing the patient's hemoglobin disorder.

Watch the distinction: A positive solubility screen is not a complete hemoglobin identification. It detects a property associated with hemoglobin S but cannot establish trait, disease, or all accompanying variants.

33. Reactive and neoplastic leukocytes

Reactive leukocyte changes often show a range of maturation: bands and earlier granulocytes may appear during strong inflammatory stimulation, and reactive lymphocytes vary in size and appearance. Concern rises when circulating blasts, a relatively uniform abnormal population, dysplasia, or multiple cytopenias accompany the count change. Morphology guides the next tests but rarely completes a modern hematolymphoid classification. Flow cytometry measures antigen patterns on individual cells to establish lineage and maturation features; cytochemistry can provide supporting functional clues. Cytogenetic and molecular findings identify alterations that may refine classification or management. Before interpreting an unusual population, check specimen age and smear quality, then correlate counts, morphology, and available clinical information. Escalate urgent blast findings through the laboratory's communication process while leaving disease classification to the appropriate specialist evaluation.

Worked example: A CBC shows anemia and thrombocytopenia, and smear review finds numerous circulating blasts rather than a graded left shift. These combined findings warrant prompt hematopathology review and communication under the laboratory's urgent-result process. Flow cytometry can define lineage markers, while molecular and cytogenetic studies may further characterize the process. The smear establishes a serious abnormal finding but does not, alone, provide a complete disease classification.

Watch the distinction: Immature-looking cells are not interchangeable. A reactive left shift retains a maturation sequence, whereas a prominent blast population with cytopenias demands a different investigation.

34. Platelet number and function

Before explaining a low platelet count biologically, establish that the count is real. EDTA-dependent clumping, a clot, giant platelets outside an analyzer's platelet size gate, and cellular fragments can all distort automated measurements. Inspect the smear, including its feathered edge, and use a verified alternative collection or counting method when needed. If thrombocytopenia is confirmed, combine morphology and history with other blood counts. Reduced marrow production may accompany other cytopenias; peripheral destruction or consumption may produce a different pattern, and sequestration changes circulating numbers without necessarily reducing total platelet mass. Platelet-function defects can cause bleeding despite a normal count because adhesion, secretion, and aggregation are separate from quantity. When using an alternative anticoagulant, apply a documented dilution correction only if required by that collection system and validated method.

Worked example: An analyzer reports 55 × 10³ platelets/µL and flags clumps. A smear shows platelet aggregates near the feathered edge, making the automated count unreliable. Recollect with an approved alternative anticoagulant and review the new smear and count. If that tube contains a liquid anticoagulant that dilutes the specimen, apply its validated correction before reporting; do not interpret the original 55 × 10³/µL as confirmed thrombocytopenia.

Watch the distinction: A low automated count with visible clumps is not a reliable measure of circulating platelets. Repeating the same sample on the same instrument may reproduce the artifact.

35. Primary and secondary hemostasis

Primary hemostasis forms the initial platelet plug. Platelets adhere at injury through interactions involving von Willebrand factor, activate, release mediators, and aggregate. Secondary hemostasis generates thrombin and fibrin that stabilize the plug. Natural anticoagulant pathways limit clot formation, while fibrinolysis removes fibrin as repair proceeds. Mucosal bleeding or easy bruising often draws attention to platelet or von Willebrand-related problems; deep tissue or joint bleeding can suggest a coagulation-factor problem, although patterns overlap. A normal platelet count measures quantity, not adhesive or aggregation function. PT and aPTT examine selected coagulation reactions, not the entire hemostatic system, and normal screening times do not exclude every relevant defect. Match symptoms to count, smear, coagulation tests, and targeted platelet or von Willebrand assays before narrowing the mechanism.

Worked example: A patient reports recurrent nosebleeds and heavy menstrual bleeding. Platelet count and PT are within the case's reference intervals, but a validated platelet-function assay is abnormal. The mucosal pattern and functional result direct investigation toward primary hemostasis, including platelet and von Willebrand-related mechanisms. The normal count does not rule out dysfunctional platelets, and the normal PT does not settle the question.

Watch the distinction: Normal PT and platelet count do not prove normal hemostasis. PT tests a limited pathway, and platelet number says little about adhesion, secretion, or aggregation.

36. Coagulation assays and inhibitors

PT and aPTT are screening assays for different sets of coagulation reactions; thrombin time focuses on conversion of fibrinogen to fibrin and is sensitive to some anticoagulants. Fibrinogen and D-dimer add information about substrate and fibrin turnover but lack specificity for one cause. Start a prolonged-clotting-time investigation with specimen quality: an underfilled citrate tube changes the blood-to-anticoagulant ratio, and heparin contamination can mimic a patient abnormality. A 1:1 patient-plasma and normal-plasma mix supplies missing factors. Correction suggests deficiency, while persistent prolongation suggests an inhibitor or anticoagulant effect. Incubation can reveal a time-dependent inhibitor that was initially masked. Interpret mixing results against stated criteria, then use anticoagulant checks and targeted factor or inhibitor tests. Quality-control failure must be resolved before interpreting patient patterns.

Worked example: A patient's aPTT is prolonged. A 1:1 mix with normal plasma corrects by the case's stated criterion immediately, but becomes prolonged again after incubation. The supplied factors initially compensate, while the later effect raises concern for a time-dependent inhibitor. Check collection integrity and exclude anticoagulant interference, then proceed to targeted factor and inhibitor testing; the mix alone does not identify the inhibitor.

Watch the distinction: Immediate correction on mixing does not always prove a simple factor deficiency. Some inhibitors act slowly, making an incubated mix and interference assessment necessary.

37. Building an immune response

Innate cells recognize broad danger patterns quickly and release cytokines that recruit and direct other cells. Antigen-presenting cells process material and display peptides with major histocompatibility molecules to T cells, linking early recognition to a targeted response. Activated helper T cells support B-cell proliferation, class switching, and affinity maturation; cytotoxic T cells recognize and eliminate some infected cells. IgM commonly appears early in a primary antibody response, while later class-switched antibodies can have greater affinity and different effector functions. Complement can be activated through several routes and promotes opsonization, inflammation, and membrane injury. Memory B and T cells alter the response to later exposure. In the laboratory, antibody class, avidity, antigen detection, and specimen timing provide clues, but a single serologic signal cannot reconstruct the entire immune history.

Worked example: Following vaccination, a later exposure to the same antigen produces a rapid, high-affinity antibody rise. Previously primed memory B cells can expand and differentiate quickly, with help from memory T-cell responses. That explains the stronger secondary signal compared with a first encounter. An innate response still occurs, but innate recognition alone does not account for antigen-specific immunologic memory.

Watch the distinction: A faster response after re-exposure is not simply “more inflammation.” Its antigen specificity and improved antibody affinity reflect adaptive memory and earlier selection of responsive cells.

38. Choosing an immunologic method

Choose an immunologic method by what must be detected. Agglutination makes antigen-antibody lattices visible on cells or particles; precipitation detects lattices among soluble reactants. Immunofluorescence locates bound antibody with a fluorescent label, while immunoblotting separates target proteins before probing. Enzyme and chemiluminescent immunoassays convert binding into measurable signals, with sandwich and competitive designs responding differently to analyte concentration. Flow cytometry measures fluorescence and scatter on individual cells, allowing a cell population and its marker pattern to be evaluated together. Every format has a useful concentration range and potential interference. Antibody excess can prevent lattice formation in agglutination or precipitation, while very high antigen can cause a hook effect in some sandwich assays. Dilution, controls, and an alternate method can clarify a discordant signal. Practice matching signal to mechanism with MLS(ASCP) practice questions.

Worked example: A particle-agglutination assay is nonreactive on an undiluted specimen despite strong evidence of antibody. At 1:8 and 1:16 dilutions, visible agglutination appears. Dilution has moved antibody and antigen toward a ratio that permits lattice formation, supporting a prozone effect from antibody excess. Report and interpret the result according to the validated dilution procedure rather than accepting the neat-specimen result alone.

Watch the distinction: A nonreactive neat agglutination tube does not always mean no antibody is present. Antibody excess can block the visible lattice that the assay requires.

39. Interpreting infection serology

Infectious-disease serology depends on which marker the assay detects and when the specimen was collected. An antigen result can indicate current antigen presence; an antibody result may reflect recent or remote infection, vaccination, or passive transfer. Early infection can precede detectable antibody, so a negative serology result within a window period has limited exclusion value. For hepatitis B, surface antigen, surface antibody, and core antibody answer distinct questions: vaccine-induced surface antibody does not require exposure to core antigen, whereas natural infection generally can produce core antibody. IgM class may help assess recency in a supplied algorithm, but it must be interpreted with the other markers and assay limits. Follow the stated testing sequence for screening and supplemental tests, and report discordant patterns for appropriate evaluation rather than forcing them into one category.

Worked example: A specimen is HBsAg negative, anti-HBs positive, and total anti-HBc negative. Surface antibody is present without detected surface antigen or core antibody. This pattern supports vaccine-derived immunity rather than evidence of previous natural infection, assuming valid assays and no complicating passive antibody exposure. It does not establish when vaccination occurred or answer every question about very recent exposure.

Watch the distinction: Positive anti-HBs does not always mean recovery from natural hepatitis B infection. A negative anti-HBc makes vaccination a better explanation for this marker combination.

40. Autoimmune antibody patterns

Autoantibody tests provide evidence with different levels of specificity. An antinuclear antibody screen detects reactivity against nuclear targets, but low-level positivity may occur without a matching autoimmune illness. Pattern and titer can guide follow-up; disease-associated antibodies add specificity when the clinical picture fits. Rheumatoid factor can appear in several settings, whereas anti-CCP has a different association profile. ANCA testing may use immunofluorescence and antigen-specific assays, so the reported pattern and target both matter. Complement concentrations can fall through consumption or change for other reasons; they are supportive findings rather than a diagnosis. Check assay method, strength of reaction, symptoms, and other laboratory results before interpreting a positive. The ASCP Board of Certification identifies the MLS credential; in this role, report the measured findings and escalate significant discrepancies for clinical interpretation.

Worked example: A patient without supportive symptoms has a low-titer positive ANA, while the case's disease-associated antibody panel is negative and complement results are within their stated intervals. Report the ANA titer and method accurately. The combination offers limited support for a specific autoimmune diagnosis; it does not erase the positive measurement, but it does not justify assigning disease from that measurement alone.

Watch the distinction: Treating any positive ANA as definitive disease confuses analytical detection with clinical interpretation. Titer, method, associated antibodies, and clinical findings determine how much weight it deserves.

41. Allergy and hypersensitivity evidence

Immediate allergic reactions begin when an allergen crosslinks specific IgE already bound to mast cells or basophils. Released mediators can produce symptoms within minutes. A laboratory specific IgE result shows that the immune system recognizes an allergen, but the result cannot establish whether exposure causes symptoms. Total IgE is even less specific: it may rise for several reasons and can be normal despite sensitization to one allergen. Interpret either result alongside the exposure history, symptom timing, and the substance tested. Other hypersensitivity mechanisms follow different pathways. Antibody and complement can injure cells or tissues, immune complexes can deposit and inflame tissue, and T cells can drive delayed reactions. An IgE assay therefore cannot explain every adverse reaction to food, medication, or contact exposure. The laboratory reports the measured finding and its limits; clinical evaluation establishes whether allergy is present.

Worked example: A patient has detectable peanut specific IgE, yet regularly eats peanuts without symptoms. The result supports sensitization because peanut reactive IgE is present. The repeated symptom free exposures do not support a clinical peanut allergy on these facts. Reporting the assay result accurately preserves that distinction. A contact rash appearing two days after an exposure would also call for consideration of a delayed mechanism, rather than interpretation through peanut IgE alone.

Watch the distinction: Treating any positive specific IgE result as proof of allergy overlooks symptom free sensitization. Neither the size of the signal nor an elevated total IgE replaces an exposure history.

42. Patterns of immune deficiency

Localize an immune defect by asking what each test measures. Quantitative IgG, IgA, and IgM describe circulating antibody abundance, while vaccine response studies assess whether antibody production works after antigen exposure. Flow cytometry counts B, T, and natural killer cell subsets; a normal count does not prove normal function. A screening complement assay examines activity across a pathway, with component studies helping locate an abnormal step. Low immunoglobulins plus few B cells suggest a problem involving the cells that generate antibodies. Preserved B cell numbers with poor functional responses suggest a different humoral defect. Reduced T cells raise concern for cellular immunity, while abnormal complement function can point to a pathway defect even when lymphocyte counts are preserved. Check age, treatment, protein loss, and specimen handling before assigning a pattern. The laboratory findings guide further investigation rather than define a precise disorder alone.

Worked example: A patient has markedly reduced IgG, IgA, and IgM, few circulating B cells, and T cell counts within the supplied reference intervals. Together, the low antibody concentrations and B cell count point toward impaired humoral cell production. Preserved T cell numbers make an isolated numerical T cell defect less likely. Functional antibody responses and specialist studies are still needed to characterize the defect; the counts alone cannot establish its cause.

Watch the distinction: Normal lymphocyte numbers do not prove normal immune function. A patient may have enough B cells but produce poor antigen specific responses, so functional testing can change the interpretation.

43. HLA and transplant compatibility

HLA molecules vary among people, making them important targets in transplant compatibility assessment. Typing describes donor and recipient HLA antigens. Antibody testing asks whether the recipient has antibodies that recognize particular antigens, often after pregnancy, transfusion, or a previous transplant. A donor specific antibody is especially relevant when its target is present on the proposed donor. In a cell based crossmatch, recipient serum is tested against donor cells; a positive result indicates binding or another assay specific compatibility signal. Solid phase antibody assays and cell crossmatches measure related but different properties, so their results can disagree. Consider antibody strength, specificity, assay format, and known interference before interpretation. The laboratory should confirm sample identity and pass the complete results to the transplant compatibility team, which integrates them with the broader clinical assessment.

Worked example: A recipient's antibody screen identifies reactivity against an HLA antigen found on the proposed donor, and the donor cell crossmatch is positive. Those two findings reinforce concern that recipient antibody recognizes donor cells. Confirm specimen and donor identity, review the assay controls, and communicate both results to the transplant compatibility team. The laboratory can describe the immunologic signal; it cannot determine transplant suitability from these findings alone.

Watch the distinction: Assuming that every positive HLA antibody test predicts the same transplant risk ignores whether the donor carries the target antigen and whether a cell crossmatch supports the finding.

44. Immunoassay interference checks

An immunoassay result depends on its binding design. In a sandwich assay, captured analyte generally increases the measured signal; in a competitive assay, analyte generally reduces it. Heterophile antibodies or rheumatoid factor can bridge assay antibodies and create a false signal. Biotin can disrupt methods that use streptavidin binding, with the apparent direction of error depending on assay format. Cross-reacting molecules may also bind the assay reagent. Antibody excess can prevent lattice formation in an agglutination test, producing prozone. Extreme analyte excess can prevent proper sandwich formation, producing a high dose hook effect. When a result conflicts with the clinical picture or related tests, inspect the assay design, controls, exposure history, and dilution behavior. Blocking reagents or an alternate method can help identify interference, but dilution must be validated before a corrected concentration is reported.

Worked example: A patient's competitive free thyroxine result is high, while sandwich TSH is low. The patient reports substantial biotin use. In assays that rely on biotin and streptavidin, interference can falsely increase the competitive result and falsely decrease the sandwich result. Confirm the methods used, review supplement timing, and repeat with an appropriate method or after a suitable interval established by the laboratory. Do not treat the paired results as independently confirmed physiology.

Watch the distinction: A plausible combination of hormone results does not exclude assay interference. Shared reagent chemistry can push two assay formats in opposite directions and make an erroneous pattern look coherent.

45. Getting a useful microbiology specimen

Specimen quality begins with the anatomical question. Material from a superficial surface may reflect colonizers, while aspirated fluid or tissue from a deep process can better represent the involved site. Collect before antimicrobial therapy when feasible because treatment may reduce recovery, and record prior treatment for interpretation. Use a container and transport conditions appropriate to the requested organism: drying harms many bacteria, oxygen exposure can impair anaerobe recovery, and some viral assays require a specified transport medium. Fungal, mycobacterial, and parasitic investigations may need different volumes, containers, or collection times. Label the exact source, not merely “wound” or “fluid,” because the same isolate can mean different things in different sites. Review collection, transport delay, Gram stain, and growth pattern together before deciding whether an organism warrants further workup. The phlebotomy technician guide reinforces patient identification and collection fundamentals.

Worked example: A superficial swab from a draining wound grows several skin organisms, while a separately collected deep tissue sample yields one predominant organism and inflammatory cells are seen on its Gram stain. The deep specimen offers stronger evidence about the involved site because its collection reduced surface contamination. Work up that isolate according to the laboratory's source based process, while reporting the swab's mixed growth in its collection context.

Watch the distinction: Calling every organism from a wound swab the cause of infection ignores collection depth and normal surface flora. Source quality can matter more than the apparent length of the isolate list.

46. Detection and identification methods

Methods answer different microbiology questions. A stain shows structures and cell reactions quickly but often gives only a presumptive identity. Culture demonstrates growth under the conditions supplied, allowing isolation and further testing, yet organisms may fail to grow after treatment or when their requirements are unmet. Biochemical tests identify patterns of metabolism; MALDI TOF compares a colony's protein spectrum with a reference library. Antigen tests detect a target molecule, while nucleic acid amplification detects a genetic sequence. Neither a detected antigen nor a detected sequence necessarily demonstrates current viability. Interpretation also depends on specimen site: the same organism may be meaningful in a sterile site and expected flora at a colonized surface. Check the method's target, specimen suitability, controls, and identification confidence before connecting an analytical finding to clinical significance.

Worked example: After treatment, a respiratory specimen is positive by a nucleic acid assay but produces no growth in culture. The molecular result establishes that the target sequence was detected in that specimen. The culture result establishes only that the organism was not recovered under the culture conditions used. Residual nucleic acid, reduced viable burden, and collection or culture limitations remain possible; the pair does not prove ongoing viable infection.

Watch the distinction: Equating a molecular positive with living organisms overstates what amplification measures. Likewise, a negative culture after therapy cannot erase a valid molecular finding or prove that the original finding was false.

47. Distinguishing gram-positive isolates

Begin gram positive identification with morphology and arrangement, then use reactions in sequence. Cocci in clusters suggest staphylococci, whereas chains or pairs often direct attention toward streptococci or enterococci. Catalase usually separates staphylococci from streptococci, provided the test is performed on a suitable colony without blood agar carryover. Coagulase supports identification of Staphylococcus aureus among staphylococci, though a complete method specific identification may require confirmation. Hemolysis helps sort streptococci but is only one feature of the workup. Gram positive bacilli need their own context: some are expected skin contaminants in isolated blood cultures, while others are significant in sterile material or repeated cultures. Interpret the number of positive sets, collection sites, time course, and patient context before treating an isolate as contamination. Potentially significant blood culture findings require prompt communication through the laboratory's established pathway.

Worked example: Two independently collected blood culture sets yield gram positive cocci in clusters. Colonies are catalase positive and coagulase positive. That sequence supports a presumptive Staphylococcus aureus identification, and recovery from multiple sets strengthens concern for a significant bloodstream finding. Verify identification according to the method and communicate promptly under the laboratory's notification process; do not dismiss the result as ordinary skin flora solely because the organism is a staphylococcus.

Watch the distinction: Using “gram positive cocci” as a final identification skips decisive reactions. It also hides a major difference between coagulase positive S. aureus and possible skin contaminants that require contextual assessment.

48. Gram-negative and anaerobic workups

Gram negative rods need a pattern of results, not one reaction. Many Enterobacterales ferment glucose and are oxidase negative, whereas common nonfermenters use different metabolic pathways and may be oxidase positive. Fastidious organisms may grow only under particular atmosphere or nutritional conditions, so limited growth on routine media can be a clue rather than an exclusion. Inspect colony appearance, oxidase result, glucose use, and a validated identification method together. Source matters especially for anaerobes: a deep aspirate or tissue protected from oxygen is more suitable than a superficial swab. Oxygen exposure can suppress susceptible anaerobes before culture, and a negative aerobic culture cannot rule them out. For a deep abscess, check whether both aerobic and anaerobic pathways received adequate material. Preserve appropriate containment and refer unusual or hazardous isolates when routine identification cannot resolve them safely.

Worked example: A deep abscess yields an oxidase positive gram negative rod that does not ferment glucose in the stated tests. This pattern argues against a typical Enterobacterales identification and supports further nonfermenter workup. The collection record shows only an aerobic swab was submitted, so anaerobic recovery cannot be evaluated reliably. Request an appropriately collected protected specimen if clinically available, while continuing identification of the organism already recovered.

Watch the distinction: Labeling every gram negative rod as an Enterobacterales member ignores metabolism and oxidase results. A negative aerobic culture also says little about anaerobes when collection or transport exposed them to oxygen.

49. Mycobacteria and fungi

An acid fast stain detects organisms whose cell walls retain the stain after acid decolorization; it does not, by itself, identify a species. Concentration can improve detection in a dilute specimen, while decontamination reduces competing flora but may also lower recovery if excessive. Culture establishes growth for later identification, and molecular tests can provide faster target specific information, subject to their own coverage and controls. Fungal identification similarly combines specimen relevance with colony and microscopic features. Yeasts and molds differ in growth form, and some molds show structures that prompt special handling or referral rather than routine open bench manipulation. A finding from a sterile site carries different weight from one on a colonized surface. Report presumptive results accurately, communicate findings requiring urgent action, and maintain containment appropriate to the suspected organism until identification and handling decisions are settled.

Worked example: A concentrated respiratory specimen has a positive acid fast smear, while culture and species identification are pending. Report the smear as an acid fast finding through the laboratory's urgent pathway and handle subsequent material with the required containment. Do not name Mycobacterium tuberculosis from the smear alone: other acid fast organisms and method limitations remain possible. Culture and a suitable identification assay address the species question.

Watch the distinction: A positive acid fast smear is not a species identification. Assigning a named pathogen before confirmatory workup can misdirect communication, even though the presumptive result still deserves prompt escalation.

50. Parasites and viruses

Choose parasite testing from the organism's life cycle and the specimen likely to contain its diagnostic stage. Stool concentration can increase recovery of eggs or cysts, but a direct preparation may better preserve motility when examined promptly. Specialized stains, antigen assays, or molecular tests may target organisms missed by a routine ova and parasite examination. Shedding can vary over time, so one negative specimen may have limited exclusion value. Blood and tissue parasites require their own collection timing and morphology or molecular approach. For viruses, a nucleic acid assay is most useful when the target is present at the sampled site and time; antigen tests and serology answer different questions. Antibody may reflect a later response or prior exposure, while an early negative antibody test may precede seroconversion. Record site, timing, and method before interpreting a negative result.

Worked example: One stool ova and parasite examination is negative, but exposure history and symptoms keep a parasitic process under consideration. The negative result means no target was seen in that sample by that method. Intermittent shedding and the method's organism coverage limit exclusion. Review the suspected parasite and choose additional collections or a targeted antigen, stain, or molecular assay as indicated, rather than repeating an unsuitable method without a clear purpose.

Watch the distinction: One negative stool examination does not exclude every intestinal parasite. Organisms differ in shedding and diagnostic stage, and routine microscopy cannot detect all targets equally well.

51. Antimicrobial susceptibility decisions

A minimum inhibitory concentration, or MIC, is the lowest tested drug concentration that prevents visible growth under the method's stated conditions. It becomes a susceptibility category only after applying a breakpoint appropriate to the organism, drug, method, and stated version. The number alone is not a universal measure of clinical effectiveness. Before release, verify that the quality control strain result lies within its supplied range and that inoculum density, medium, incubation, and endpoint reading were acceptable. An inoculum that is too heavy or an ambiguous endpoint can alter the apparent MIC. If the result is outside the tested range, report it with the method's inequality rather than inventing a precise value. Resistance mechanisms may warrant confirmatory work when the phenotype is unexpected. The laboratory reports a validated category and flags unusual patterns for review; treatment selection remains a clinical decision.

Worked example: A case states that an organism drug pair is susceptible at MICs of 1 mg/L or less, resistant above 4 mg/L, and intermediate between those bounds. Its measured MIC is 2 mg/L, which is greater than 1 and no greater than 4, so the supplied category is intermediate. If the control strain falls within its stated range and testing conditions pass review, report that category. If control fails, withhold the patient interpretation and investigate.

Watch the distinction: Calling an MIC of 2 mg/L “susceptible” because it sounds small ignores the supplied breakpoint. Categories belong to a specific organism, drug, and method, and failed quality control invalidates interpretation.

52. Source context and molecular controls

A microbiology result gains meaning from its source. Growth in a normally sterile site raises different questions from growth on skin or mucosa, where colonization is common. Mixed growth can suggest contamination in one collection context yet be expected in another. Molecular assays add another layer: a negative patient target requires valid extraction and amplification controls. An internal control that fails may indicate inhibition, extraction loss, or another process failure, so “not detected” is unsupported. A positive extraction blank suggests contamination before amplification, while a positive amplification blank points toward later carryover. Compare the failure pattern across controls and specimens before choosing a corrective step. Recollect when specimen quality is the problem; repeat extraction or amplification when the corresponding process failed. Findings suggesting a hazardous sentinel organism require cessation of routine manipulation and the specified escalation route.

Worked example: A sterile site specimen is target negative by PCR, but its internal amplification control also fails. The patient result is invalid because the reaction has not demonstrated that amplifiable material could be detected. First review the extraction control and inhibition indicators; then repeat through the appropriate stage or seek a new specimen if needed. The sterile source makes a valid result important, but it cannot turn a failed reaction into a negative report.

Watch the distinction: A blank patient target channel is not automatically a negative result. When its internal control fails, inhibition or extraction failure can hide a true target, so validity must be resolved first.

53. Identity and specimen traceability

Every laboratory result must remain connected to the correct patient and specimen from collection through reporting. Use the required identifiers at collection, then preserve the link among container label, order, accession number, aliquots, storage location, and any referral record. A transfer into a secondary tube creates another point where identity can be lost, so the new container needs traceable labeling. Compare collection site, time, anticoagulant, and requested tests during accessioning because a correctly named tube can still be unsuitable for the analysis. When identifiers conflict, stop the affected process and preserve the original materials and records while the discrepancy is resolved under the laboratory's acceptance rules. A repeat analytical measurement cannot determine whose specimen was tested. Clear documentation should show the discrepancy, decision, recollection if needed, and disposition of any results already produced.

Worked example: A tube label carries one patient identifier, while its requisition carries another. Hold the specimen and prevent result release. Check the accession trail and collection record without altering the original evidence. If identity cannot be established to the laboratory's required standard, obtain a newly identified specimen and document why the first was rejected. Even a technically perfect assay on the first tube would not resolve whose result it represents.

Watch the distinction: Matching the tube to the order by room number or presumed collection sequence is unsafe. Neither clue verifies patient identity when primary identifiers disagree, and later testing cannot repair that gap.

54. Risk-based laboratory safety

Choose safety controls by identifying the likely exposure route and task. Gloves and routine barriers reduce contact risk, while procedures that generate aerosols call for containment, sealed equipment, or both. A centrifuge failure can leave infectious material in droplets and aerosols, so opening and cleanup must follow the facility's hazard specific procedure. Chemical hazards require their own controls: consider volatility, corrosiveness, incompatible substances, ventilation, and the safety data sheet. Sharps should be handled with devices and disposal steps that minimize puncture exposure. Waste segregation follows the material's actual hazard rather than its appearance. After an exposure, first address immediate safety, then report and document through the designated occupational process so assessment is timely. Laboratory personnel should not improvise a cleanup method from a remembered rule for a different organism or chemical.

Worked example: A tube suspected of containing a transmissible organism breaks inside a centrifuge. Keep the centrifuge closed, restrict access, and notify the appropriate personnel. Allow aerosols to settle for the interval specified by the facility procedure, then use the prescribed protective equipment, containment, disinfectant, and cleanup sequence. Document the incident and any exposure. Opening the lid immediately to inspect the spill could increase aerosol exposure.

Watch the distinction: Wearing gloves alone does not control an aerosol released by centrifugation. The exposure route determines whether enclosure, waiting, respiratory protection, or other prescribed measures are needed.

55. Reading quality-control patterns

Quality control shows whether an analytical process is behaving as expected before patient results are trusted. Plot control results in time order around a target mean and compare them with the laboratory's supplied limits and decision rules. A single extreme value may reflect a random event, such as aspiration trouble, while a persistent step to one side of the mean suggests a shift after calibration or reagent change. A gradual run in one direction suggests drift, such as deterioration. These patterns are clues rather than diagnoses: check both control levels, recent maintenance, lot changes, calibration, and instrument flags. Decide which patient results could be affected from the last acceptable control onward, investigate, correct the cause, and demonstrate acceptable performance before release. Review MLS(ASCP) practice questions with the exact decision rule supplied in each case, since the action depends on that rule.

Worked example: In a hypothetical run, five successive control results rise from 98 to 99, 100, 101, and 102 units/L; the sixth is 106 units/L, above the case's action limit of 105 units/L. The directional movement suggests drift, and the sixth result explicitly fails. Hold affected patient results, inspect reagent and calibration history, correct the cause, then obtain acceptable control results before release. The preceding trend helps locate the problem's onset.

Watch the distinction: One control point inside broad limits does not erase a developing trend. Conversely, a trend alone triggers only the action specified by the laboratory's stated decision rules.

56. Measuring method performance

Precision describes the spread of repeated results; bias describes their average difference from a reference or comparison target. Calculate coefficient of variation as standard deviation divided by mean, multiplied by 100%, so precision can be compared across concentrations. A low CV does not guarantee low bias: tightly grouped results can all be displaced. Analytical accuracy considers both effects, while clinical usefulness also depends on the decision being made with the result. For a diagnostic test, sensitivity is true positives divided by all people with the condition; specificity is true negatives divided by all people without it. Positive predictive value instead divides true positives by all positive results and changes with prevalence. When assessing a method, identify whether the supplied limit concerns imprecision, bias, total error, or diagnostic performance. Apply the matching calculation and criterion rather than treating all performance measures as interchangeable.

Worked example: A hypothetical control has mean 100 units/L and standard deviation 2 units/L. CV = 2 ÷ 100 × 100% = 2%. If the case allows imprecision up to 3%, this CV meets that criterion. Yet if a reference target is 95 units/L, bias = 100 − 95 = +5 units/L, or 5 ÷ 95 × 100% = 5.26%. Precision passes, while bias needs separate assessment against its own limit.

Watch the distinction: A small CV shows repeatability, not agreement with the true value. A method can give nearly identical results every time while remaining consistently too high or too low.

57. Calibration and ongoing verification

Calibration establishes the relationship between instrument signal and reported concentration. Calibration verification checks that this relationship remains acceptable at selected points; it does not create a new calibration. A reagent lot comparison asks whether changing materials shifts patient results, often using paired specimens across the clinically relevant range. Maintenance addresses equipment condition, while proficiency testing assesses performance on external challenges under its stated rules. These checks answer different questions, so an acceptable routine control may coexist with a clinically important lot difference if control limits are broad or the control matrix behaves differently from patient samples. Investigate a failed check by confirming specimen identity, instrument status, reagent preparation, and calculations before changing settings. Document the cause, correction, and evidence that the correction worked. If patient results may have been affected, evaluate the interval and disposition of those results.

Worked example: With a new reagent lot, three paired patient specimens read 82 versus 75, 141 versus 130, and 209 versus 194 units/L, old versus new lot respectively. New lot differences are −7, −11, and −15 units/L, all in one direction. If the case permits no more than 5 units/L difference for each pair, the lot fails comparison despite routine controls staying within broad limits. Hold release, investigate, and verify correction with acceptable comparisons.

Watch the distinction: Passing routine controls does not automatically approve a new reagent lot. Controls may miss a patient matrix effect or a shift smaller than their limits but larger than the lot criterion.

58. Molecular controls and contamination

Molecular testing usually starts by releasing and purifying nucleic acid from the specimen. Amplification copies a selected target sequence; hybridization uses complementary binding to identify a sequence, and sequencing determines the order of bases in an analyzed region. Controls locate failures. A positive control shows that the target detection system can work, while an internal control in each specimen helps reveal inhibition or extraction loss. A negative extraction control passes through sample preparation and can reveal contamination introduced early. A no template amplification control chiefly checks contamination introduced during reaction setup or later. A valid positive patient result still requires clean negative controls, since carryover can create false positives. Separate workflow areas and careful handling reduce transfer of amplified material. When a control fails, identify the stage implicated, correct it, and repeat the affected work rather than selectively accepting favorable patient results.

Worked example: Several patient extracts amplify the target, but the negative extraction control also amplifies. Because that control entered the process before extraction, contamination could have affected every sample prepared alongside it. Withhold the run's patient interpretations, inspect extraction materials and workflow, replace affected reagents or supplies, and repeat after correction. A clean no template control would narrow the likely stage but would not rescue results from a contaminated extraction batch.

Watch the distinction: Treating the negative extraction control as irrelevant because patient positives look plausible defeats its purpose. A contaminated control removes confidence that those signals came from the patients' specimens.

59. Following data through the LIS

A result travels through instrument software, an interface, middleware, and the laboratory information system before it reaches the report. At each transfer, confirm analyte identity, units, decimal placement, reference interval, flags, and patient linkage. Autoverification can release only results that satisfy its configured rules; delta checks compare a current result with a previous result and can expose transcription, specimen, or physiological changes requiring review. An audit trail should preserve what was received, changed, released, or corrected, with who and when. Unit mapping is especially hazardous because the numeric value can look reasonable after the wrong label is attached. For glucose, conversion between mmol/L and mg/dL uses approximately 18 mg/dL per mmol/L, but the interface should apply its validated conversion and rounding rules. Protect access to identifiable results throughout review and correction.

Worked example: An analyzer sends glucose 5.5 mmol/L, but the interface displays “5.5 mg/dL.” The displayed unit is wrong, so stop release and inspect the mapping. Using the stated approximate factor, 5.5 mmol/L × 18 mg/dL per mmol/L = 99 mg/dL. After validating the interface conversion and report formatting, verify affected records and document corrections where necessary. Merely changing the unit label would leave an incorrect report.

Watch the distinction: A matching numeric field does not prove a correct interface. Units and reference intervals are part of the result; attaching mg/dL to an unchanged mmol/L number can radically change its meaning.

60. Quality management and communication

Quality management connects accurate testing with reliable delivery of information. Controlled documents specify the current procedure and record its revisions; competency assessment checks whether staff can perform assigned work, not merely whether they attended training. Workflow review looks for recurring gaps in identification, turnaround, notification, or correction. When a result meets the laboratory's critical notification rule, verify it as required, contact the designated recipient, and document the result, recipient, time, and communication outcome. If contact fails, follow the escalation route rather than leaving an untracked attempt. Investigating a failure requires separating analytical error from communication failure and testing whether the corrective action prevents recurrence. A before and after comparison may show improvement, but small samples or changed case mix can limit the inference. The ASCP Board of Certification identifies the MLS credential; laboratory procedures govern the local communication workflow.

Worked example: A verified result meets the laboratory's supplied critical notification criterion, but its record has no recipient or time. Check whether notification actually occurred. Complete or repeat communication through the designated route, document the recipient and time, and assess whether any delay needs escalation. Review the workflow for why the record was incomplete, then check later cases for recurrence. Correct analytical measurement did not complete the communication process.

Watch the distinction: Treating a critical result as finished when the instrument value is verified overlooks delivery. Without a documented recipient and time, the laboratory cannot show that the finding reached the responsible person.